Glonghui, May 28 | Bank of America Securities published a research report stating that Alibaba Health's full-year results for the end of March beat expectations. The revenue trend of the Group's major business segments is stable. Due to operating cost control and efficiency improvements, net profit for the 2024 fiscal year was 883 million yuan, far higher than the bank's expectations. Gross profit increased by 3% year-on-year, in line with expectations. Bank of America Securities maintains a “buy” rating for the Group, with a target price of HK$4.5, and is expected to show good business momentum in the 2025 fiscal year. It is expected that revenue will resume positive growth, profit growth will accelerate, and benefit from the integration of newly acquired high-profit marketing businesses.
大行评级｜美银：维持阿里健康“买入”评级 年度业绩胜预期
Bank Ratings｜Bank of America: Maintaining Alibaba Health's “Buy” Rating Annual Results Outperform Expectations
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.